Biotalys refocuses biocontrol strategy to cut costs

Biotalys announced plans to refocus its business to concentrate resources on its highest-priority programs and streamline operations, a move expected to reduce total cash burn by about $23.5 million through the end of 2028.

The company said it will right-size its organizational structure and suspend early-stage activities to lower operating expenses while prioritizing development and regulatory advancement of its lead biofungicide assets. Commercial preparation will focus on markets with the strongest near-term potential, including controlled environment and specialty crop segments relevant to greenhouse growers.

“It is imperative that we deploy capital where it creates the greatest impact,” said Kevin Helash, CEO of Biotalys.

The refocus centers on the company’s most advanced programs, EVOCA NG and BioFun-6. Biotalys will continue supporting BioFun-7 with the Gates Foundation and BioIns-2 in partnership with Syngenta. Process development to achieve competitive manufacturing costs will continue through a strategic partnership with 21st.BIO. The company will also maintain its post-harvest collaboration with AgroFresh.

Biotalys said it intends to reduce its workforce by 30 employees to align costs with the new strategy. The company confirmed a cash runway into May 2026 and said it is in discussions with investors about potential financing to support the sharpened portfolio.